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ABSTRACT: Essential Thrombocytosis (ET) is a clonal disorder of unknown etiology 
involving a multipotent hematopoietic progenitor cell and is manifested clinically by the 
overproduction of platelets without a definable cause. Clinically, ET is most often 
identified incidentally when a platelet count is obtained during the course of routine 
evaluation. There are very few case reports in the pediatric age group in which peripheral 
gangrene is caused by primary thrombocytosis or essential thrombocythemia. This is a case 
report of a 5 year old male child who presented to us as peripheral gangrene of toes which 
was caused by ET, one of the Myeloproloferrative disorders. 
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INTRODUCTION
ᴪ 
 
A platelet count exceeding the upper limit is called 
thrombocytosis. The physiologic reference range of 
platelet counts is 150-400 x 10
9/L. Thrombocytosis 
is classified as either primary or secondary. 
Primary thrombocytosis (also called essential 
thrombocythemia, ET) is caused by autonomous 
production of platelets unregulated by the 
physiologic feedback mechanism to keep the count 
within the reference range. It is a subset 
of  myeloproliferative disorder (e.g. essential 
thrombocythemia, myelofibrosis with myeloid 
metaplasia, polycythemia vera, chronic myelocytic 
leukemia [rare]) 
1 The incidence of ET is estimated 
to range from 1-4 cases per 10 million people 
younger than 20 years.
2 
 
CASE REPORT 
 
We report a 5 year old boy who presented in the 
pediatric outpatient department of tertiary care 
teaching hospital, with complaints of blackening 
and swelling of four lateral toes excluding great toe 
of both legs for 1 week along with pain in both 
legs. There was no history of fever, bleeding from 
any site or trauma. 
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On examination there was blackening of four toes 
in both lower limbs excluding the hallux (Figure 
1). There was no restriction of movement and it 
was not tender. Pulsation of all peripheral pulses--
femoral artery, popliteal artery, anterior tibial 
artery, posterior tibial artery as well as dorsalis 
pedis artery was palpable.  Blood pressure was 
normal in all four extremities. All the other systems 
were within normal limits. 
 
 
Figure 1: Gangrene of four toes in both lower 
limbs excluding thumb 
 
Doppler flow study showed normal flow in dorsalis 
pedis artery bilaterally. The blood investigations 
showed haemoglobin 11.5 gm/dl, total leucocyte  Avasthi et al / Peripheral gangrene as a result of primary thrombocytosis 
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counts 7700/mm
3, differential counts (polymorphs 
56%, lymphocytes 33%, eosinophils 7%, 
monocytes 4%),  mean corpuscular volume (MCV) 
94.6fl, mean corpuscular haemoglobin (MCH) 
31pg and  mean corpuscular haemoglobin 
concentration (MCHC) 30.5%. Perpheral blood 
smear showed normocytic normochromic RBCs, no 
evidence of immature cells and increased platelets. 
Antiphospholipid antibody syndrome panel was 
negative i.e.  prothrombin time 14 seconds (INR 
ratio-1.1), APTT 31.3 seconds (control-18-32 
seconds), anticardiolipin antibody IgA 2.65 APL 
U/ml, anticardiolipin antibody IgM 3.24 MPL 
U/ml, anticardiolipin antibody IgG 6.62 GPL U/ml 
and antiphospholipid antibody IgG 3.8 GPL U/ml 
(reference value of all antibodies 0.5-10). As the 
general blood picture showed increased platelets, 
platelet count was done, which was 800 x 10
9/L. To 
exclude infection as a cause of thrombocytosis, C 
reactive protein (CRP) and D dimer assay were 
done which were fould as 6.2mg/dl (upper 95
th 
percentile 11.0mg/dl) and116.0ng/ml (reference-
57-495.5 ng/ml) respectively. As by the above 
investigations, iron deficiency anemia and infection 
which can produce thrombocytosis were excluded 
and it was presumed to be primary thrombocytosis. 
To confirm the diagnosis bone marrow aspiration 
was done. It showed hypercellularity, 
megakaryocytic hyperplasia and giant 
megakaryocytes. Bone marrow aspiration 
confirmed the diagnosis of primary thrombocytosis. 
The patient was put on aspirin for 3 months. After 
3 months platelets came down to 300 x 10
9/L with 
spontaneous resolution of the gangrene. 
 
DISCUSSION 
 
Thrombotic or hemorrhagic complications caused 
by reactive or secondary thrombocytosis are 
described only anecdotally and must be regarded as 
extremely rare. However, in children with 
autoimmune disease or vasculitis, such as 
Kawasaki syndrome, thromboses do develop. In 
Kawasaki syndrome, this occurs particularly in the 
coronary arteries.  In patients with primary 
nonfamilial thrombocytosis, which is a 
myeloproliferative disorder, the frequency of 
thrombosis and/or hemorrhage widely varies 
among various reports (20-84% for thrombotic 
complications and 4-41% for bleeding 
complications). However, these statistics are for 
adult patients, and incidences of hemorrhagic and 
thrombotic complications in primary 
thrombocytosis of children are not known.
1 In one 
study, 0.5% of hospitalized children had a platelet 
count more than 800 x 10
9/L.
3  On the basis of 
experiences in young adults with primary 
thrombocytosis, these complications may occur less 
often in children than in adults.
4  Teofili et al
4 
reported no thrombosis in children with essential 
thrombocytosis, as opposed to 10 of 32 patients in a 
study of adults. On the other hand, Dame and 
Sutor
5 reported that about 30% of children with 
essential thrombocytosis had thromboembolic or 
hemorrhagic complications at the time of diagnosis 
or later, and that about 20% of initially 
asymptomatic children had these complications 
later. These figures are similar to those of adults. 
Bleeding mainly involves the mucous membranes 
and skin (e.g. GI hemorrhage, hemoptysis, post 
surgical bleeding, bruises, epistaxis). Thrombosis 
involves the veins and arteries. 
Preston
6 published a case series of six adult patients 
in which peripheral gangrene was caused by ET. 
Papadonikolakis et al
7 also published a case report 
of 34 year old male who had Raynaud’s 
phenomenon presented with peripheral gangrene. 
Cecil
8 published the single institutional experience 
of 39 cases of adult patients with mean age of 
55.5+14.5 years, of which 14 had thrombosis as a 
complication. They concluded that the 
identification of Janus kinase 2
 mutation (JAK 2) 
probably defines a sub entity in ET with aggressive 
behaviour as evidenced by splenomegaly, higher 
total counts and transformation to polycythemia 
rubra vera. 
Use of pharmacologic agents to prevent thrombotic 
complications in primary or ET is controversial, 
even in the internal medicine literature, because no 
laboratory studies offer predictive value in terms of 
the risk of thrombosis or hemorrhage. Tefferi et al
9 
recommend their use only in patients older than 60 
years, individuals with a history of thrombosis, or 
persons with cardiovascular risk factors, virtually 
eliminating pediatric patients. 
Symptomatic patients with essential 
thrombocytosis (ET) should receive treatment to 
lower their platelet count. For pediatric use, 
anagrelide or hydroxyurea is recommended. In a 
study by Harrison et al
10, adult patients (median 
age, about 60 y) were randomly assigned to receive 
low-dose aspirin plus hydroxyurea or anagrelide. 
Significantly more patients in the anagrelide arm 
than in the hydroxyurea arm reached the study 
endpoint. The authors concluded that hydroxyurea 
plus aspirin was more effective than anagrelide 
plus aspirin in preventing complications in adults 
with ET. 
We report this case because a rare cause for 
reversible peripheral dry gangrene in the pediatric 
population was diagnosed. We have given aspirin, 
by which the platelet counts came down to normal 
with no recurrence of thrombosis. 
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